NOVT NOVANTA INC Insider Trading

CEO Matthijs Glastra sold 6,500 shares for $1,047,340.22 via scheduled 10b5-1 plan on 2026-07-02.

Matthijs Glastra, CEO of Novanta Inc, executed 5 separate sales totaling 6,500 shares for $1,047,340.22 on 2026-07-02 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-11. The transactions reduced his holdings from 36,261 shares to 29,761 shares, a -17.9% reduction. Since this sale was scheduled under a 10b5-1 plan rather than discretionary, it reflects a predetermined execution framework rather than a market timing decision. At the time of the filing, the stock is trading at $147.85, which is -14.0% from the 52-week high of $171.85 and down -5.4% over the prior 30 days, though it is up 20.8% over 90 days.

CEO Matthijs Glastra sells 6,500 shares for $1,096,272.70 via scheduled 10b5-1 plan on 2026-06-02

Matthijs Glastra, CEO of Novanta Inc (NOVT), executed six separate sales totaling 6,500 shares for $1,096,272.70 on 2026-06-02, reducing his holdings from 42,761 to 36,261 shares (15.2% reduction). The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-09-11, indicating this was a scheduled, non-discretionary execution rather than a timing-based decision. The blended average sale price was $168.66, compared to the current market price of $160.53, placing the transaction near the 52-week high ($171.85). Glastra's recent prior trades at NOVT (all in May 2026) showed 30-day returns ranging from +7.3% to +26.4%, though these outcomes are unrelated to the scheduled nature of the current filing.

CEO Matthijs sells 7,500 shares of NOVT for $1.1M; retains 42,761 shares post-sale

Matthijs Glastra, NOVANTA's Chief Executive Officer, sold 7,500 shares for $1,128,244.14 at a price of $155.71, currently -6.0% from the 52-week high and +20.8% over the past 30 days. The CEO retains substantial holdings of 42,761 shares post-transaction. This sale occurs under a pre-arranged 10b5-1 trading plan adopted on 2025-09-11, indicating a scheduled divestiture rather than a discretionary market-timing decision. The company shows solid financial performance with $257.7M in quarterly revenue and $21.1M in net income, though the P/E ratio of 105.93 reflects elevated valuation expectations.

NOVT CEO Glastra sells ~6,500 shares worth $852K, continuing a pattern of consistent sales with no recent buys.

CEO Matthijs Glastra has completed a multi-tranche sale totaling approximately $852,000 in NOVANTA stock, reducing his position across four separate transactions. This sale is notable because Glastra's insider track record consists entirely of sales—his twenty prior trades in this stock and elsewhere have all been exits, with no purchases on record. Most recently, he sold shares on multiple occasions in March and again in April, making this latest May sale part of an unbroken pattern of consistent selling activity. The underlying company is profitable with strong revenue growth, suggesting the sales are driven by portfolio management or liquidity strategy rather than fundamental deterioration. However, the complete absence of buying activity, even as the company posts healthy fundamentals, underscores a consistent conviction to reduce exposure that investors may find worth monitoring, particularly given Glastra's prominent role as CEO.

CEO Glastra sold 6,500 NOVT shares at $130.05; recent same-ticker sells all showed 30d declines of -12.1% to -15.7%

Glastra Matthijs, Chief Executive Officer, sold 6,500 shares at $130.05, reducing holdings by -10.3% to 56,761 shares. His prior five sales at NOVT on 2026-03-02 all showed 30-day declines ranging from -12.1% to -15.7%, establishing a consistent same-ticker pattern of immediate post-sale price erosion. The current stock price of $132.40 is -9.6% from the 52-week high of $146.39, and the 30-day change of +16.3% reflects a recent recovery from those earlier sell-offs. The P/E ratio of 111.26 is notably elevated relative to fundamentals (quarterly revenue $247.8M, net income $10.7M), suggesting the stock may be pricing in significant forward expectations. The cluster of sales within a compressed timeframe on 2026-03-02 followed by this April sale warrants attention to whether the CEO perceives valuation constraints or other operational considerations.

CFO Buckley sells 9,957 shares (10.0K) for $1,162,651.44 via scheduled 10b5-1 plan

Robert Buckley, Chief Financial Officer of Novanta Inc, executed 4 separate sales totaling 9,957 shares for $1,162,651.44 at a blended average price of $116.77 on March 16, 2026. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-13, meaning the sales were scheduled and non-discretionary rather than driven by current market conditions or insider judgment. His post-transaction holding of 96,616 shares represents a 9.3% reduction versus his pre-transaction position of 106,573 shares. The scheduled nature of this plan removes any inference about timing or conviction.

CEO Glastra sells 6,500 shares across 8 transactions for $899,239.12 at NOVT on 2026-03-02

Glastra Matthijs, Chief Executive Officer of NOVANTA INC, executed 8 separate sales on 2026-03-02 totaling 6,500 shares for $899,239.12, reducing his holdings by 9.3% to 63,261 shares. The multiple tranches sold at prices ranging from $131.92 to $140.48, with a blended average price of $138.34, which is 1.6% below the current price of $140.64 and 3.9% below the 52-week high of $146.39. NOVT's stock has appreciated 4.7% over the past 30 days and 19.8% over 90 days, reflecting positive recent momentum. Across his open-market trading history on all tickers, the CEO's 20 prior sells averaged -0.1% 30-day return and -5.2% 90-day return, with a 61.54% well-timed rate; however, his 5 prior trades at NOVT show 4 measurable 30-day outcomes (all positive: +2.4% to +4.6%) and 0 measurable 90-day outcomes on this specific ticker.

CEO Glastra sells 7,500 NOVT shares for $1.1M at $145.04; 8 sales in 10 days suggest planned liquidation.

Glastra Matthijs, CEO of Novanta, sold 7,500 shares on 2026-02-10 at $145.04, bringing his holdings from 64,867 shares to 57,367 shares and reducing his stake by 11.6%. This sale is part of a concentrated liquidation pattern: same-ticker history shows 5 prior trades at NOVT, including four separate sales on 2026-02-02 (just 8 days prior), followed by this sale 8 days later. The sales cluster is noteworthy given the CEO's substantial remaining position of 57.4K shares and the stock's strong recent performance (+34.2% over 90 days, +6.0% over 30 days), placing the current price at $139.29 only 6.7% below the 52-week high of $149.30. While the company carries a premium valuation (P/E of 94.11) and modest profitability ($10.7M net income on $247.8M revenue), the pattern of frequent open-market sales within days—rather than scheduled or formulaic transactions—merits tracking to assess whether this reflects a shift in the CEO's conviction regarding near-term value or simply personal capital reallocation.

CEO Matthijs sold 6,500 shares ($878.5K) at $134.52–$137.38 on 2026-02-02 via pre-arranged 10b5-1 plan.

Glastra Matthijs, Chief Executive Officer of Novanta Inc (NOVT), executed 4 separate sales totaling 6,500 shares for $878,458.68 on 2026-02-02 at prices ranging from $134.52 to $137.38, with a blended average price of $135.15. This transaction reduced his post-transaction holdings to 64,867 shares from 71,367 shares (a -9.1% reduction). The sale was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-09-11, meaning it was scheduled and non-discretionary. Since the transaction is governed by a pre-arranged plan, no timing-based inference about management intent or conviction can be drawn.

NOVT CEO Glastra sold 7,500 shares at $140.00 on 2026-01-21; 10b5-1 plan, post-transaction holdings 71,367 shares

CEO Matthijs Glastra executed a sale of 7,500 shares at $140.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-11, reducing his holdings from 78,867 shares to 71,367 shares. Because this transaction is part of a scheduled trading plan rather than a discretionary trade, it reflects a predetermined execution schedule established months prior and does not signal an opportunistic or reactive investment decision. The sale represents a 9.5% reduction in his pre-transaction shareholding, bringing his remaining stake to 71,367 shares.